European Union revamps toxicology testing in attempt to limit animal use, improve prediction.
G. Sinha
DOI: https://doi.org/10.1093/JNCI/DJJ250
2006-06-07
Journal of the National Cancer Institute
Abstract:The U.K. clinical trial disaster earlier this year underscored at least one thing: Animal models poorly mimic human physiology. Prior studies of the TeGenero leuke-mia drug, a monoclonal antibody, showed no sign of the catastrophic reaction that hospitalized six people. As companies increasingly develop protein-based therapies that specifi cally target human cells, animal models are likely to prove even worse at predicting how humans will respond. " These types of drugs make up more than 50% of new-drug applications, " said Thomas Hartung, Ph.D., head of the European Centre for the Validation of Alternative Methods (EVCAM) of the European Union Joint Research Centre. " We can't use toxicology that is 60 years old. " Now new tests are in the works. In March the center approved six new toxicology screens that promise to speed up research on some drugs while making others safer. These are the latest of several tests to spring out of a European initiative to minimize animal testing. Since 1991, the center has focused on reducing, replacing, and refi ning existing animal-based toxicology screens for drug, chemical, and consumer product regulation. Once the center validates a test, companies within the EU are required to use it. The United States, with its relatively tame animal rights movement, has approached the issue more lightly. No single agency is responsible for creating new tests and, once developed, they are not mandated. In recent years, however, the search for alternatives has grown beyond what some consider soppy sentiment. As the gap between powerful, targeted drugs and the technology used to screen them for toxic side effects widens, alternative testing can also improve safety. Of the new European tests, for example , fi ve detect pyrogenic contaminants in drugs — bacteria that infi ltrate injectable or intravenous drugs during manufacturing and cause lethal immune reactions. The tests rely on cultured human white blood cells and might replace two existing, more expensive methods — the Limulus assay and testing on rabbits. The new techniques improve on both methods. The Limulus assay picks up only gram-negative bacteria, whereas the new cell culture methods detect both gram-negative and gram-positive bacteria , as well as viruses and fungi, Hartung said. Drugs not suitable for the Limulus test, such as monoclonal antibodies and other biological compounds, typically use rabbits instead, but they only test whether there is contamination — not how much. What's more, a drug that …